KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Total Debt (2016 - 2025)

Historic Total Debt for Travere Therapeutics (TVTX) over the last 13 years, with Q2 2025 value amounting to $68.8 million.

  • Travere Therapeutics' Total Debt changed N/A to $68.8 million in Q2 2025 from the same period last year, while for Jun 2025 it was $68.8 million, marking a year-over-year change of. This contributed to the annual value of $68.7 million for FY2024, which is N/A changed from last year.
  • As of Q2 2025, Travere Therapeutics' Total Debt stood at $68.8 million.
  • Travere Therapeutics' Total Debt's 5-year high stood at $68.8 million during Q2 2025, with a 5-year trough of $6.9 million in Q1 2023.
  • Its 5-year average for Total Debt is $29.6 million, with a median of $7.4 million in 2021.
  • Per our database at Business Quant, Travere Therapeutics' Total Debt plummeted by 5747.13% in 2021 and then tumbled by 540.54% in 2022.
  • Over the past 5 years, Travere Therapeutics' Total Debt (Quarter) stood at $7.4 million in 2021, then fell by 5.41% to $7.0 million in 2022, then fell by 1.43% to $6.9 million in 2023, then soared by 895.33% to $68.7 million in 2024, then rose by 0.23% to $68.8 million in 2025.
  • Its Total Debt stands at $68.8 million for Q2 2025, versus $68.8 million for Q1 2025 and $68.7 million for Q4 2024.